NCT06235905View on ClinicalTrials.gov

Open-Label of SPN-820 in Adults With Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

August 18, 2024

Study Completion Date

August 18, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

NV-5138

NV-5138 is a novel, orally bioavailable, mechanistic target of rapamycin complex 1 (mTORC1) signaling enhancer

Trial Locations (1)

92591

Viking Clinical Research, Temecula

Sponsors
All Listed Sponsors
collaborator

Supernus Pharmaceuticals, Inc.

INDUSTRY

lead

Navitor Pharmaceuticals, Inc.

INDUSTRY